Current Options and New Developments in the Treatment of Haemophilia

National Hemophilia Foundation. Fast facts. 2006 [online]. Available from URL: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=259&contentid=476 [Accessed 2010 Nov 10] Evatt BL. The tragic history of AIDS in the hemophilia population, 1982–1984. J Thromb Haemost 2006 Nov; 4(11): 2295–301 Pool JG, Gershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate [letter]. Nature 1964 Jul 18; 203: 312 Brinkhous KM, Shanbrom E, Roberts HR, et al. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate: treatment of classical hemophilia and hemophilia with inhibitors. JAMA 1968 Aug 26; 205(9): 613–7 Webster WP, Roberts HR, Thelin GM, et al. Clinical use of a new glycine-precipitated antihemophilic fraction. Am J Med Sci 1965 Dec; 250(6): 643–51 Kasper CK, Kipnis SA. Hepatitis and clotting-factor concentrates [letter]. JAMA 1972 Jul 31; 221(5): 510 Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands’ diseases. Lancet 1977 Apr 23; 1(8017): 869–72 Makris M, Preston FE, Triger DR, et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990 May 12; 335(8698): 1117–9 Gill JC, Menitove JE, Wheeler D, et al. Generalized lymphadenopathy and T cell abnormalities in hemophilia A. J Pediatr 1983 Jul; 103(1): 18–22 Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989 Oct 26; 321(17): 1141–8 Aronstam A, Congard B, Evans DI, et al. HIV infection in haemophilia: a European cohort. Arch Dis Child 1993 Apr; 68(4): 521–4 Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984 Nov 22–28; 312(5992): 326–30 Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984 Nov 22–28; 312(5992): 342–7 Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A: recombinant Factor VIII Study Group. N Engl J Med 1990 Dec 27; 323(26): 1800–5 Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007 Aug 4; 370(9585): 439–48 Ludlam CA, Powderly WG, Bozzette S, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet 2006 Jan 21; 367(9506): 252–61 Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 2006 Jan; 132(1): 13–24 Lofqvist T, Nilsson IM, Berntorp E, et al. Haemophilia prophylaxis in young patients: a long-term follow-up. J Intern Med 1997 May; 241(5): 395–400 Fischer K, Van Den Berg M. Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia 2003 Jul; 9(4): 376–81 Blatt PM, Lundblad RL, Kingdon HS, et al. Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med 1974 Dec; 81(6): 766–70 Lusher JM. Myocardial necrosis after therapy with prothrombin-complex concentrate [letter]. N Engl J Med 1984 Feb 16; 310(7): 464 Hampton KK, Makris M, Kitchen S, et al. Potential thrombogenicity of heat-treated prothrombin complex concentrates in haemophilia B. Blood Coagul Fibrinolysis 1991 Oct; 2(5): 637–41 Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002 Mar; 8(2): 83–90 Santagostino E, Mannucci PM, Gringeri A, et al. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thromb Haemost 1994 Jun; 71(6): 737–40 Choo KH, Gould KG, Rees DJ, et al. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 1982 Sep 9; 299(5879): 178–80 Anson DS, Choo KH, Rees DJ, et al. The gene structure of human anti-haemophilic factor IX. EMBO J 1984 May; 3(5): 1053–60 Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005 Jan 15; 105(2): 518–25 Rodriguez NI, Hoots WK. Advances in hemophilia: experimental aspects and therapy. Pediatr Clin North Am 2008 Apr; 55(2): 357–76, viii Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007 Aug 9; 357(6): 535–44 Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006 Jun; 4(6): 1228–36 Petrini P, Lindvall N, Egberg N, et al. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991 Fall; 13(3): 280–7 Funk M, Schmidt H, Escuriola-Ettingshausen C, et al. Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Ann Hematol 1998 Oct; 77(4): 171–4 Kreuz W, Escuriola-Ettingshausen C, Funk M, et al. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998 Jul; 4(4): 413–7 Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999 Jun; 105(4): 1109–13 Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs: the Orthopaedic Outcome Study Group. J Intern Med 1994 Oct; 236(4): 391–9 Smith PS, Teutsch SM, Shaffer PA, et al. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996 Sep; 129(3): 424–31 Szucs TD, Offner A, Kroner B, et al. Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group. Haemophilia 1998 Jul; 4(4): 498–501 Lillicrap D. The role of immunomodulation in the management of factor VIII inhibitors. Hematology Am Soc Hematol Educ Program 2006; 421–5 Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26(2): 179–88 Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003 Feb; 29(1): 23–30 Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs [letter]. Haemophilia 1998 Jan; 4(1): 68 Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009 Apr 16; 360(16): 1618–27 Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007 Mar; 13(2): 149–55 Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006 Jan 1; 107(1): 46–51 Astermark J, Altisent C, Batorova A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010 Sep 1; 16(5): 747–66 Simon TL, Snyder EL, Solheim BG, et al., editors. Rossi’s principles of transfusion medicine. 4th ed. Chichester: Blackwell Publishing Ltd, 2009 Lusher JM, Shapiro SS, Palascak JE, et al. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980 Aug 21; 303(8): 421–5 Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII: a double-blind clinical trial. N Engl J Med 1981 Sep 24; 305(13): 717–21 Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983 Nov; 62(5): 1135–8 Turecek PL, Varadi K, Gritsch H, et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999; 77 Suppl. 1: 72–9 Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007 Jan 15; 109(2): 546–51 Hilgartner M, Aledort L, Andes A, et al. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients: FEIBA Study Group. Transfusion 1990 Sep; 30(7): 626–30 Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors: French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997 Jun; 77(6): 1113–9 Monroe DM, Hoffman M, Oliver JA, et al. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998 Mar; 9 Suppl. 1: S15–20 Parameswaran R, Shapiro AD, Gill JC, et al., HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005 Mar; 11(2): 100–6 Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006 Feb; 4(2): 367–71 Key NS, Nelsestuen GL. Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Semin Hematol 2004 Jan; 41 (1 Suppl. 1): 51–4 Colowick AB, Bohn RL, Avorn J, et al. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000 Sep 1; 96(5): 1698–702 Hoffman R, BenzJr EJ, Shattil SJ, et al., editors. Hematology: basic principles and practice. 5th ed. Philadelphia (PA): Churchill Livingston Elsevier, 2009 Ewing NP, Sanders NL, Dietrich SL, et al. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988 Jan 1; 259(1): 65–8 Lacroix-Desmazes S, Moreau A, Sooryanarayana, et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999 Sep; 5(9): 1044–7 Nilsson IM, Berntorp E, Zettervall O, et al. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to Factor VIII in hemophilia A patients. Blood 1990 Jan 15; 75(2): 378–83 Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry: report of the factor VIII and IX Subcommittee. Thromb Haemost 1994 Jul; 72(1): 155–8 DiMichele DM, Kroner BL, North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002 Jan; 87(1): 52–7 Coppola A, Margaglione M, Santagostino E, et al., AICE PROFIT Study Group. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009 Nov; 7(11): 1809–15 Frenkel EB, Stastny P. Use of 6-mercaptopurine in the control of a circulating anticoagulant against anti-hemophilic globulin [abstract]. Clin Res 1965; 13: 272 Sultan Y, Kazatchkine MD, Algiman M, et al. The use of intravenous immunoglobulins in the treatment of factor VIII inhibitors. Semin Hematol 1994 Apr; 31 (2 Suppl. 4): 65–6 Mauz-Korholz C, Korholz D, Gobel U. Rapid elimination of a high-titered F VIII inhibitor by high dose recombinant F VIII combined with high dose immunoglobulin infusion [letter]. Thromb Haemost 1997 Aug; 78(2): 959 Cobcroft R, Tamagnini G, Dormandy KM. Serial plasmapheresis in a haemophiliac with antibodies to FVIII. J Clin Pathol 1977 Aug; 30(8): 763–5 Revesz T, Matyus J, Goldschmidt B, et al. Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a haemophiliac with inhibitors. Arch Dis Child 1980 Aug; 55(8): 641–3 Francesconi M, Korninger C, Thaler E, et al. Plasmapheresis: its value in the management of patients with antibodies to factor VIII. Haemostasis 1982; 11(2): 79–86 Raish RJ, Witte DL, Goldsmith JC. Successful cardiac surgery following plasmapheresis in a patient with hemophilia B. Transfusion 1985 Mar–Apr; 25(2): 128–30 Bona RD, Pasquale DN, Kalish RI, et al. Porcine factor VIII and plasmapheresis in the management of hemophiliac patients with inhibitors. Am J Hematol 1986 Feb; 21(2): 201–7 Barnes C, Rudzki Z, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure. Haemophilia 2000 Nov; 6(6): 693–5 Watt RM, Bunitsky K, Faulkner EB, et al. Treatment of congenital and acquired hemophilia patients by extra-corporeal removal of antibodies to coagulation factors: a review of US clinical studies 1987–1990. Hemophilia Study Group. Transfus Sci 1992 Apr; 13(2): 233–53 Freiburghaus C, Berntorp E, Ekman M, et al. Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995. Haemophilia 1998 Jan; 4(1): 16–20 Galvez A, Gomez-Ortiz G, Diaz-Ricart M, et al. Desmopressin (DDAVP) enhances platelet adhesion to the extracellular matrix of cultured human endothelial cells through increased expression of tissue factor. Thromb Haemost 1997 May; 77(5): 975–80 Villar A, Jimenez-Yuste V, Quintana M, et al. The use of haemostatic drugs in haemophilia: desmopressin and antifibrinolytic agents. Haemophilia 2002 May; 8(3): 189–93 Nilsson IM, Mikaelsson M, Vilhardt H, et al. DDAVP factor VIII concentrate and its properties in vivo and in vitro. Thromb Res 1979; 15(1–2): 263–71 Kobayashi I. Treatment of hemophilia A and von Willebrand’s disease patients with an intranasal dripping of DDAVP. Thromb Res 1979; 16(5-6): 775–9 de la Fuente B, Kasper CK, Rickles FR, et al. Response of patients with mild and moderate hemophilia A and von Willebrand’s disease to treatment with desmopressin. Ann Intern Med 1985 Jul; 103(1): 6–14 Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001 Jan; 233(1): 88–96 Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 1997 Oct 2; 389(6650): 498–501 Spira J, Plyushch OP, Andreeva TA, et al. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006 Dec 1; 108(12): 3668–73 Spira J, Plyushch OP, Andreeva TA, et al. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A. Thromb Haemost 2008 Sep; 100(3): 429–34 Powell JS, Nugent DJ, Harrison JA, et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008 Feb; 6(2): 277–83 Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001 Mar; 22(5): 405–17 Lillicrap D. Extending half-life in coagulation factors: where do we stand? Thromb Res 2008; 122 Suppl. 4: S2–8 Ngo JC, Huang M, Roth DA, et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008 Apr; 16(4): 597–606 Shen BW, Spiegel PC, Chang CH, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008 Feb 1; 111(3): 1240–7 Gale AJ, Radtke KP, Cunningham MA, et al. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006 Jun; 4(6): 1315–22 Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci U S A 1997 Oct 28; 94(22): 11851–6 Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002 May; 19(5): 569–77 Dumont JA, Low SC, Peters RT, et al. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. Biodrugs 2006; 20(3): 151–60 Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol 2005 Jan; 15(1): 5–9 Chuah MK, Collen D, VandenDriessche T. Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost 2004 Apr; 30(2): 249–56 Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol 2008 Mar; 140(5): 479–87 Viiala NO, Larsen SR, Rasko JE. Gene therapy for hemophilia: clinical trials and technical tribulations. Semin Thromb Hemost 2009 Feb; 35(1): 81–92 Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003 Sep–Oct; 80(1-2): 148–58 Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X 1. Science 2003 Oct 17; 302(5644): 415–9 St. Jude Children’s Research Hospital. Dose-escalation study of a self complementary adeno-associated viral vector for gene transfer in hemophilia B [Clinical-Trials.gov identifier NCT00979238]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 17] Children’s Hospital of Philadelphia. Gene transfer for subjects with hemophilia B factor IX deficiency [ClinicalTrials.gov identifier NCT00515710]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 17] Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009 Jan 29; 360(5): 447–58 Brower C, Thompson A. GeneReviews: hemophilia B. 2008 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/books/NBK1495/ [Accessed 2010 Nov 10] Brower C, Thompson A. GeneReviews: hemophilia A. 2008 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/books/NBK1404/ [Accessed 2010 Nov 10] Kemball-Cook G. The Haemophilia A Mutation, Structure, Test and Resource Site (HAMSTeRS). 2007 [online]. Available from URL: http://hadb.org.uk/ [Accessed 2010 Nov 10] Gorini L, Kataja E. Phenotypic repair by streptomycin of defective genotypes in E. coli. Proc Natl Acad Sci U S A 1964 Mar; 51: 487–93 Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996 Apr; 2(4): 467–9 Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997 Nov; 3(11): 1280–4 Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007 Apr; 47(4): 430–44 Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008 Aug 30; 372(9640): 719–27 PTC Therapeutics. Study of ataluren (PTC124®) in hemophilia A and B [ClinicalTrials.gov identifier NCT00947193]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 17]